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ABSTRACT 
 
Background: Patients with B-cell chronic lymphocytic leukemia (B-CLL) have hetero-
geneous clinical courses, thus several biological parameters need to be added to the cur-
rent clinical staging systems to predict disease outcome. Recent immunophenotypic stud-
ies performed mainly in Western populations have demonstrated the prognostic value of 
CD38 and ZAP-70 expression in B-CLL. Objectives: To investigate the expression pat-
tern of a variety of membrane antigens on leukemic cells from Iranian patients with CLL 
and to find out if there are any differences in the expression of these markers between in-
dolent and progressive groups.  Methods: In the present study, peripheral blood samples 
from 87 Iranian patients with B-CLL were analysed by flow cytometry. Results: In all 
cases, the neoplastic cells displayed B-CLL phenotype (CD5+/CD19+/sIg+). The vast ma-
jority of the cases expressed CD23, but failed to stain for CD3 or CD14. The leukemic 
cells of most patients expressed CD27 (84/87, 95.4%) and CD45RO (74/87, 83.9%) 
molecules, suggesting a memory B-cell phenotype. Comparison between the indolent 
(n=42) and progressive (n=37) patients revealed significantly higher frequency and inten-
sity of CD38 expression in progressive group (40.5%) compared to indolent (11.9%) pa-
tients (p<0.05). None of the other membrane antigens were differentially expressed in 
these two groups of patients. Conclusion: Our results obtained in an Asian ethnic popula-
tion confirm and extend previous findings obtained from Western populations regarding 
the association of CD38 expression and disease progression in B-CLL. 
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INTRODUCTION 
 
B-cell chronic lymphocytic leukemia (B-CLL) is the most common type of leukemia in 
the Western societies (1). The malignant B-cells are derived from clonal expansion and 
gradual accumulation of CD5+/CD19+/sIg low lymphocytes in the bone marrow, blood 
and lymphoid tissues. These cells appear to be phenotypically mature, but are function-
ally compromised (2).  
Differential diagnosis of CLL from other mature B cell lymphoid leukemias is largely 
based on clinical and laboratory findings. A variety of laboratory methods such as blood 
cell counting and morphology, immunophenotyping, histopathological and chromoso-
mal analyses are being used to identify the leukemic cells, the type of malignancy and to 
some extent disease severity and prognosis (3).  
There is a compelling need for novel prognostic parameters in addition to the current 
prognostic features including the Rai or Binet staging system, lymphocyte doubling 
time (LDT), serum levels of B2-microglobulin, soluble CD23 (4), bone marrow infil-
tration patterns and cytogenetic abnormalities (5). In recent years a number of biologi-
cal prognostic factors have been developed (6). Among them, analysis of the muta-
tional status of the expressed immunoglobulin heavy chain variable genes (IgVH) has 
allowed to identify two clinical subgroups within CLL with different progression pat-
terns. Patients with unmutated leukemic cells have more aggressive clinical course, 
whereas, patients with mutated malignant cells have frequently indolent disease (7). 
Unfortunately, VH mutation analysis is complex, expensive, time consuming and not 
routinely undertaken in most laboratories. Accordingly, many attempts have been 
made to identify a marker (or markers) that could be as useful as IgVH mutational 
state in the prognostic assessment of patients with CLL. Membrane expression of 
CD38 molecule was the first marker that was found to correlate with IgVH mutation 
(8). Intracytoplasmic detection of ZAP-70 enzyme was subsequently revealed to be 
correlated with IgVH mutation and B-CLL prognosis (9). Patients with progressive 
disease are more likely to express both molecules, whereas the leukemic cells from 
indolent patients tend to be negative for both markers (8). Association between dis-
ease progression and immunophenotypic profile of leukemic cells has not been widely 
studied in B-CLL patients from other ethnic populations. The prevalence of B-CLL 
has previously been shown to be lower in Asian populations (10). Interestingly, the 
frequency of VH gene family expression has also been demonstrated to be different in 
B-CLL patients from a variety of Western populations, compared to Iranian and Japa-
nese patients (11). These findings suggest that there might be some molecular differ-
ences between different groups of B-CLL patients, depending on their ethnic back-
ground. The present study is the first immunophenotypic investigation conducted in 
Iranian progressive and indolent B-CLL patients. 
 
 
MATERIALS AND METHODS 
 
Patients. Twenty milliliters of heparinized peripheral blood was collected from 87 CLL 
patients attending the Oncology Clinics of Imam Khomeini and Firozgar Hospitals, af-
filiated to Tehran University of Medical Sciences and Iran University of Medical Sci-
ences, respectively. A consent letter was taken from all patients and the study was ap-
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proved by the Ethical Committee of Tehran University of Medical Sciences. The diag-
nosis was based on immunophenotypic analysis, cell blood count, cell morphology and 
clinical symptoms. The age range of patients was 39–84 years with a median of 63 
years. Disease staging was accomplished by Rai staging system. Fifty four patients were 
male and 33 were female. The patients were classified into indolent (n=42), progressive 
(n=37) and newly-diagnosed (n=8) groups. Disease progression was identified on the 
basis of either of the following criteria: lymphocyte count doubling time of less than 1 
year; progression to a more advanced Rai stage; development of systemic symptoms; 
development of Richter’s syndrome; downward trend of hemoglobin (Hb) concentration 
or platelet count to below the normal range (Hb < 13.5 g/dl for males and < 11.5 g/dl for 
females; platelet count <150×109/l) even when not meeting the criteria for stage III or 
IV disease. Possession of one of these characteristics was sufficient to qualify as pro-
gressive disease (12). Twenty one patients, mostly at stage 3 or 4, were under chemo-
therapy at sampling time. The major clinical characteristics of our patients are summa-
rized in Table 1. 
Cell Preparation. Peripheral blood mononuclear cells (PBMCs) were separated using 
Histopaque (Sigma, St Louis, MO, USA) density-gradient centrifugation. Isolated 
cells were washed twice with RPMI-1640 medium (Invitrogen, Paisley, Scotland) and 
counted. 
Immunophenotyping. Cell surface antigens were analysed by flow cytometry as de-
scribed (11). Isolated PBMCs were stained with appropriate dilutions of monoclonal 
antibodies conjugated with fluorescein isothiocyanate (FITC) or phycoerythrin (PE) 
specific for human:   myeloid lineage [CD14 (clone TUK4)], B cell lineage [CD19 
(clone HD37), CD20 (clone B-Ly1) and CD23 (clone MHM6)], T cell lineage [CD3 
(clone UCHT1) and CD5 (clone DK23)], CD38 (clone AT 13/5), CD27 (clone M-
T271), CD45 (clone T29/33), CD45RA (clone 4KB5), CD45RO (clone UCHL1), HLA-
DR (clone AB3), and polyclonal FITC- conjugated rabbit F(abƍ)2 anti-kappa, lambda 
light chains and Mu heavy chain (IgM).  Fluorochrome conjugated isotype control anti-
bodies of irrelevant specificity served as negative controls (Cytomation; Dako Corp, 
Glostrup, Denmark). Detection of CD5 and CD19 was performed by double staining. 
For surface staining, cells were washed with RPMI-1640 and then incubated with 10 µl 
of conjugated antibodies in phosphate-buffered saline (PBS) containing 0.1% NaN3 for 
30 min at 4ºC. Cells were then washed twice with washing solution (PBS, 0.2% bovine 
serum albumin, 0.1% NaN3 and 0.5 mM ethylenediaminetetraacetic acid) and fixed 
with 1% paraformaldehyde in cold PBS. Cells were finally examined by Partec PAS II 
flow cytometer (Partec, Munster, Germany). The criterion for surface marker positivity 
was expression by at least 20% (30% for CD38) of the leukemic cells after subtraction 
of background staining with isotype-matched control antibodies. 
Statistical Analysis. The analysis was performed using the SPSS statistical package. 
Comparison of the expression of various antigens in indolent and progressive groups 
and their association to clinical characteristics of patients was performed using the 
Mann-Whitney U test, t test and Pearson Chi-Square, as appropriate. Logistic regression 
was used to predict progression status on the basis of surface antigen expression. For-
ward stepwise (likelihood ratio) tests were carried out, with p=0.05 entry and 0.10 re-
moval. Statistical significance was assigned when P values were less than 0.05.  
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Table 1. Clinical and laboratory characteristics of the Iranian B-CLL patients 
 
No Pa-tients Age Sex
WBC 
¯103
Lym 
(%) 
Rai 
stage 
Treat-
ment 
Disease Pro-
gression 
Disease Dura-
tion (yr) No 
Pa-
tients Age Sex
WBC 
¯103
Lym 
(%) 
Rai 
stage 
Treat-
ment 
Disease Pro-
gression 
Disease Dura-
tion (yr) 
1              CLL1 60 M 35.6 87 0 - Indolent 2 46 CLL46 40 M 116 94 II - Progressive 1 
2                  
                  
                 
                 
                  
                    
                 
                   
                 
               
                    
               
                
                
               
                 
                
                   
                
               
                    
              
                   
                    
               
              
               
                   
                    
              
                    
                 
                  
                 
                 
               
               
                   
              
               
                  
         
                   
                  
CLL2 57 M 45.3 92 II - Indolent 4 47 CLL47 53 F 607 80 I - Indolent 1
3 CLL3 72 M 19.6 77 0 - Indolent 2 48 CLL48 67 F 57.3 75 0 - Indolent
 
1
4 CLL4 52 M 111 94 I - Progressive
 
3 49 CLL49 70 F 17.3 85 0 - ND -
5 CLL5 55 M 21.9 75 0 - Indolent 2 50 CLL50 69 F 40 91 0 - Indolent 1
6 CLL6 73 M 23.6 74 0 - Indolent 2 51 CLL51 66 F 46 83 0 - Indolent 2
7 CLL7 79 M 14.6 75 0 - Indolent 4 52 CLL52 65 M 20 90 0 - Progressive 2
8 CLL8 58 F 116.2
 
96 0 - Progressive 5 53 CLL53 67 M 20 85 0 - Indolent 1
9 CLL9 59 M 8.7 79 IV
 
Chlo+Flu
 
Progressive
 
2 54 CLL54 50 M 17.7 74 0 - Progressive 1
10 CLL10 47 M 38.7 85 0 - Indolent 13 55 CLL55 82 M 170 89 II - Progressive
 
1
11 CLL11 61 M 28.5 62 0 - Indolent 5 56 CLL56 76 F 36.7 84 II - ND -
12 CLL12 71 F 29.7 85 II - Indolent 7 57 CLL57 67 F 103 92 0 - Progressive 6
13 CLL13 67 F 57.1 87 0 - Indolent 2 58 CLL58 56 M 39.2 89 0 - Indolent 9
14 CLL14 58 M 39.4 80 0 - Indolent 2 59 CLL59 70 F 28 80 0 - Indolent 4
15 CLL15 78 M 16.3 81 III Pred+Chlo
 
Indolent 12 60 CLL60 71 M 38.3 86 0 - Indolent 1
16 CLL16 65 M 72.4
 
89 IV
 
Pred
 
Indolent 10 61 CLL61 50 F 32 76 0 - Indolent 1
17 CLL17 64 M 17 64 I - Indolent 5 62 CLL62 50 M 53.7 87 0 - Progressive 1
18 CLL18 61 M 34.1
 
83 III - Indolent 5 63 CLL63 45 M 890 95 II - Progressive 1
19 CLL19 63 M 32 83 0 - Indolent 2 64 CLL64 65 M 355 87 II - Progressive 1
20 CLL20 62 M 36.2 78 0 - Indolent 7 65 CLL66 67 F 75.5 82 0 - Indolent 1
21 CLL21 65 F 13.6 80 0 - Indolent 1 66 CLL68 55 M 19.8 80 0 - Indolent 1
22 CLL22 70 M 48.7 90 0 - Indolent
 
7 67 CLL69 61 M 98.4 96 IV Pred+Chlo
 
Progressive 2
23 CLL23 58 M 65 82 0 - ND - 68 CLL70 60 F 21.2 75 II Pred Progressive
 
7
24 CLL24 60 F 22.3 86 0 - Indolent 1 69 CLL71 58 F 3.2 70 0 Pred+Chlo Indolent 4
25 CLL25 73 M 103 95 II - Progressive 2 70 CLL72 79 M 76.4 93 IV Pred+Chlo Progressive 2
26 CLL26 64 M 50 94 I - Progressive
 
4 71 CLL73 75 F 18.4 84 NI Pred+Chlo Indolent 3
27 CLL27 73 F 21.2 74 0 - Indolent 2 72 CLL74 55 M 46.9 85 IV Pred+Chlo
 
 Progressive 2
28 CLL28 53 M 26.1 89 0 - Progressive 2 73 CLL75 59 F 87.7
 
95 II - Indolent 14
29 CLL29 76 M 30.6 75 0 - Progressive 3 74 CLL76 47 M 2.9 43 IV Flud Progressive 11
30 CLL30 62 M 13.2 86 0 - Progressive
 
2 75 CLL77 50 M 168.4 91 IV Chlo
 
Progressive 4
31 CLL31 51 M 27.1 75 0 - ND - 76 CLL78 45 F 27.7 81 II - Progressive 2
32 CLL32 73 M
 
30.4 82 0 - Indolent 4 77 CLL79 83 M 23.7 87 IV Chlo
 
Progressive 2
33 CLL33 71 F 41.4 87 0 - Progressive
 
2 78 CLL80 65 M 139.8
 
96 III - Progressive 1
34 CLL34 53 M
 
255 82 II - Indolent 5 79 CLL81 67 M 172 80 IV Flud Progressive 8
35 CLL35 64 F 22.5 79 0 - Indolent
 
5 80 CLL82 50 M 74.1
 
78 III Chlo Progressive
 
1
36 CLL36 60 F 31.1 69 0 - ND - 81 CLL83 64 F 64 94 III Pred+Chlo ND -
37 CLL37 52 M 24.7 80 0 - Progressive 7 82 CLL84 70 F 50 90 0 Pred+Chlo
 
 Indolent 2
38 CLL38 51 F 37.7 85 II - Progressive
 
11 83 CLL85 55 M 33.1 86 II Chlo Progressive 5
39 CLL39 39 F 23.2 74 0 - Indolent
 
4 84 CLL86 80 F 150 97 II Pred+Chlo Progressive 1
40 CLL40 58 F 39 89 0 - ND - 85 CLL87 81 M 181 87 IV Pred+Chlo Progressive 2
41 CLL41 69 F 18.5 70 0 - Indolent
 
1 86 CLL87 82 M 234 94 II Chlo+Alo
 
 Progressive 1
42 CLL42 73 M
 
36.9 69 II - ND - 87
 
CLL89
 
75
 
M
 
29
 
89
 
IV
 
Flud
 
Progressive
 
7
 43 CLL43 67 F 41.8 84 0 - Progressive
 
2
44 CLL44 70 M
 
16.3
 
85 0 - Indolent 5
45 CLL45 58 F 25 60 I - Progressive 1
WBC: white blood cell count; Lym: lymphocytes; Hb: hemoglobin; PLT: platelet; LAP: lymphadenopathy; SPM: splenomegaly; HPM: hepatomegaly; M: male; F: female; Chlo: chlorambucil; Flud: fludarabine; Pred: prednisolone; Alo: allopurinol; ND: newly 
diagnosed; NI: not identified 
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RESULTS 
 
General Immunophenotypic Features of Leukemic Cells. The expression of 15 sur-
face membrane molecules (CD3, CD5, CD14, CD19, CD20, CD23, CD27, CD38, 
CD45, CD45RA, CD45RO, HLA-DR, ț and Ȝ light chains and µ heavy chain) was de-
termined in leukemic cells from 87 Iranian CLL patients. Representative results are il-
lustrated in Figure 1 and cumulative results are depicted in Figure 2. In all cases the 
neoplastic cells displayed B-CLL phenotype (CD5+/CD19+/sIg+) with high expression 
of CD45 and HLA-DR. Leukemic cells from the vast majority of samples expressed 
CD20 and CD23 but failed to express CD3 or CD14. Peripheral mononuclear cells from 
most patients expressed CD45RA (85.1%) and CD45RO (83.9%), these two molecules 
were co-expressed in 70 % of patients. There was no significant difference in the ex-
pression of CD45 isoforms between indolent and progressive patients (Table 2). The 
mean fluorescence intensity (MFI) of CD45 isoforms was also similar in these two 
groups of patients (data not presented). The expression pattern of CD27 was similar to 
that of the CD45 and its isoforms, with no significant difference between indolent 
(97.6%) and progressive (95.4 %) patients (Table 2). 
 
 
Table 2. Comparison of CD20, CD23, CD27, CD38, CD45RA and CD45RO  
expression with clinical characteristics of Iranian patients with CLL 
 
 No (%) of 
patients 
CD20+ CD23+ CD27+ 
 
CD38+ CD45RA+ CD45RO+ 
All patients 87 73 (83.9) 77 (88.5) 83 (95.4) 24 (27.6) 74 (85.1) 73 (83.9) 
Indolent 42 (48.3)† 32 (76.2) 38 (90.5) 41 (97.6) 5 (11.9)* 33 (78.6) 33 (78.6) 
Progressive 37 (42.5) 35 (94.6) 33 (89.2) 35 (94.6) 15 (40.5) 33 (89.2) 33 (89.2) 
Treated 21 (24.1) 18 (85.7) 17 (81) 18 (85.7) 7 (33.3) 17 (81) 18 (85.7) 
Untreated 66 (75.9) 55 (83.3) 60 (90.9) 65 (98.5) 17 (25.8) 57 (86.4) 55 (83.3) 
‡ Rai stage: I 48 (55.2) 43 (89.6) 42 (87.5) 47 (97.9) 11 (22.9) 40 (83.3) 40 (83.3) 
II 22 (25.3) 16 (72.7) 21 (95.5) 21 (95.5) 8 (36.4) 20 (90.9) 16 (72.7) 
III 16 (18.4) 13 (81.3) 14 (87.5) 14 (87.5) 5 (31.3) 13 (81.3) 16 (100) 
Gender: Male 54 (62.1) 44 (81.5) 48 (88.9) 51 (94.4) 15 (27.8) 46 (85.2) 45 (83.3) 
Female 33 (37.9) 29 (87.9) 29 (87.9) 32 (97) 9 (27.3) 28 (84.8) 28 (84.8) 
LAP 19 (21.8) 16 (84.2) 18 (94.7) 17 (89.5) 6 (31.6) 16 (84.2) 16 (84.2) 
SPM 27 (31) 21 (77.8) 23 (85.2) 24 (88.9) 9 (33.3) 22 (81.5) 21 (77.8) 
HPM 4 (4.6) 2 (50) 3 (75) 4 (100) 0 3 (75) 4 (100) 
Anemia 11 (12.6) 10 (90.9) 10 (90.9) 9 (81.8) 5 (45.5) 9 (81.8) 11 (100) 
Thrombocytopenia 11 (12.6) 8 (81.8) 10 (90.9) 10 (90.9) 5 (45.5) 11 (100) 11 (100) 
-†Data are presented as number (%), *P value<0.05, determined by Pearson Chi-Square test, ‡ Modified Rai staging system, LAP: 
 lymphadenopathy, SPM: splenomegaly, HPM: hepatomegaly 
 
 
Of 87 CLL patients, 62 (71.3%) cases expressed ț immunoglobulin light chain and 25 
(28.7%) expressed Ȝ light chain (ratio 2.5:1). The ț/Ȝ ratio was lower in indolent (2:1) 
compared to progressive (4:1) patients, though the difference did not reach statistical 
significance. 
Expression Profile of CD38 Molecule in CLL Subgroups. A given leukemic popula-
tion was considered positive for CD38 when 30% of the B-CLL cells expressed the 
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Figure 1. Representative flow cytometry results for 4 patients with B-CLL 
The samples belong to patients with indolent (CLL58 and CLL59) or progressive (CLL26 and CLL28) disease. Clinical and laboratory characteristics of the 
patients are given in Table 1. 
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molecule (8). Accordingly, 24 (27.6%) cases were CD38+ of whom 5 (11.9%) and 15 
(40.5%) cases displayed indolent and progressive diseases, respectively (p=0.02). Four 
CD38+ samples belonged to newly diagnosed patients. Overall, the range of CD38 ex-
pression in the leukemic cells of CLL patients was from 0.1% to 87%. It is interesting to 
note that only 10 patients expressed CD38 above the level of 50%, 9 of whom were in 
progressive group and the last one was from the newly-diagnosed group. Stronger ex-
pression of CD38 was also observed in progressive group when mean fluorescent inten-
sity was taken into consideration, but the difference was statistically insignificant (data 
not shown). No significant differences were found for CD38 expression and the clinical 
staging of the patients, though CD38+ leukemic B-cells were slightly higher in stage II 
and III patients compared to those at stage I (Table 2). 
According to the forward stepwise logistic regression approach, CD38 was found to be 
the only significant predictor of progression status of patients, among all other markers 
tested (p=0.001; with a 95% confidence interval of 1.184-1.566). 
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Figure 2. Expression pattern of major immunophenotypic markers in Iranian CLL patients  
Baseline denotes a cutoff expression value (20%) arbitrary assigned to differentiate positive and 
negative results. 
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DISCUSSION 
 
The incidence of B-CLL in Asian populations has been reported to be lower than in 
Western people, where it constitutes the most abundant type of leukemias (1). Due to its 
limited abundance, the immunophenotypic features of the B-CLL tumor cells have not 
been widely investigated in Asian populations. Recent results mainly reported in West-
ern B-CLL patients have demonstrated association between CD38 expression and pro-
gressive disease (13). The results of this study conducted for the first time in an Iranian 
population, confirm and extend previous findings. 
Light chain expression was demonstrated in all of our cases. Of 87 CLL patients, 71.3% 
and 28.7% expressed ț and Ȝ light chains on their leukemic B cells (ratio 2.5:1), respec-
tively. This is in agreement with the results of Stamatopoulos et al. (14), in which from 
276 CLL patients 64.9% expressed ț and 35.1% were expressing Ȝ light chains but 
slightly different from the study of Hulkkonen et al. (15), in which from 35 CLL cases, 
54% and 46% of the cases expressed ț and Ȝ light chains. In the report of Lewis et al. 
(16), of 23 CLL cases expressing surface Ig, 65.2 and 34.8% were ț and Ȝ light chain 
positive, respectively. 
We confirmed that CD38 expression is a clinically relevant marker (30% expression 
on leukemic B-CLL cells), for predicting disease progression. This finding is in agree-
ment with the study of Hayat et al (13).
CD38 was initially proposed as a surrogate marker for the absence of IgVH gene muta-
tion in CLL patients by Damle et al (8). Although a subsequent study by Hamblin et al. 
(17) failed to establish a clear cut correlation with the absence of mutations in IgVH 
genes, it has been confirmed by many studies that CD38 expression can be considered 
as an independent and reliable negative prognostic marker in CLL (18). CD38 protein is 
a type II single-chain transmembrane molecule displaying a canonical molecular weight 
of approximately 45 kDa (19). It has been suggested that CD38 performs as a receptor 
in B-CLL cells upon translocation into the lipid raft and physical association with the 
BCR/CD19 complex. Environmental conditions were found to be crucial in modulating 
CD38 surface expression and functions: IL-2 was identified as a surrogate indicator of 
the relevance of soluble factor(s), working in synergy to determine the final biologic 
effects. The signals delivered by CD38 and IL-2 induce proliferation and prolonged 
survival of a subpopulation of B-CLL cells (20). Also it has been shown by Deaglio et 
al. (21) that CD38+ B-CLL cells bind to murine fibroblasts transfected with the CD31 
ligand with resulting increased growth and survival. Further this work shows that 
CD38/CD31 crosstalk is part of an intricate network of communication between neo-
plastic cells and bystander non neoplastic cells. Indeed, CD38/CD31 interactions lead to 
increased B-CLL proliferation and survival by means of a direct cooperation with 
CD100, a cell surface receptor member of the semaphorin family, which interact with 
CD72 (a low affinity ligand, co expressed by B-CLL cells), and with plexin-B1 (high-
affinity ligand, expressed by stromal and endothelial cells)(22, 23). 
CD38 mediated signals are followed by increased expression of cell surface CD100 and 
simultaneous down-modulation of CD72, which is the prototype of negative regulation 
of B cells (24). It has been shown by Burger et al (25) that nurse like cells as profes-
sional supporters of B-CLL cells, express high levels of CD31 and plexin-B1. This sup-
ports the role of CD38 in which CD38+ cells can interact with nurse like cells with the 
final result of a significant improvement in their growth potential. Collectively, it can be 
suggested that CD38 is not merely a marker in B-CLL, but it is a receptor that plays an 
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important role in the pathogenesis of B-CLL, controlling the proliferation and survival 
of malignant B-CLL cells.  
Our findings showed that most of our CLL cases (95.4%) displayed a strong expression 
of CD27 on their leukemic B-CLL cells. This is in agreement with the finding of Vilpo 
and coworkers (26), in which all of 22 CLL cases expressed CD27 on their leukemic B 
cells. Also other studies confirmed the expression of CD27 in their CLL cases. CD27 is 
accepted as a memory cell marker, as previously proposed (27). CD27 is a transmem-
brane disulfide-linked homodimer belonging to nerve growth factor receptor (NGFr) 
superfamily, a group of homologous molecules involving in the processes of lympho-
cyte differentiation and selection that include the two tumor necrosis factor (TNF) re-
ceptors, the B cell antigen CD40 and the lymphocyte activation antigen CD30, as well 
as APO-1/Fas (CD95), a molecule which controls lymphocyte survival (28). Expression 
of CD27 had been considered previously as a peculiar finding of leukemic CD5+ B-CLL 
cells; as a matter of fact normal follicular CD5+ mantle zone cells, which represent the 
non neoplastic counterpart of B-CLL cells, are CD27 negative (29). Cross linking of the 
CD27 antigen on T cells provides a costimulatory signals that, in concert with T-cell 
receptor cross linking, can induce T-cell proliferation and cellular immune activation 
(30). The expression of CD27 and also its ligand (CD70) on B-CLL leukemic cells may 
have the same function as T cells on the proliferation and to some extent survival of 
these leukemic cells. 
In our study we did not find any differential expression of CD45 isoforms in our CLL 
groups (indolent vs. progressive). Our results did not confirm the findings of Vilpo and 
his coworkers (26) who  reported a correlation in the expression of CD45RO with mu-
tated CLL patients (most of indolent patients with a good prognosis). High expression 
of CD45RO and CD27 in our CLL patients suggests that B-CLL cells may be more ma-
ture cells, perhaps of memory type. But it is unclear why these cells also express 
CD45RA at the same level as CD45RO. Isoforms of CD45 marker are generated by al-
ternative splicing of three exons (exon 4, 5, and 6) in mRNA (31). CD45RO (P180) and 
CD45RA (P205, 220) have been most intensively studied because CD45RO is widely 
regarded as a marker of memory lymphocytes (32). The expression pattern of CD45 iso-
forms is different in various cell types. The CD45RO isoform is expressed in the major-
ity of granulocytes and monocytes. Naïve T cells and the majority of normal B cells ex-
press the high molecular isoform of CD45 (CD45RA), and only a few peripheral blood 
B cells express low levels of CD45RO (32). In the tonsil the majority of T cells express 
CD45RO and only a few B cells express this marker (33). The molecular studies by Yu 
and coworkers (34) showed that the transition from CD45RA high phenotype to 
CD45RA low phenotype in CLL is associated with the generation of the exon 5 splice 
product of CD45 mRNA. The CD45 isoforms expressed by various B cell malignancies 
can be assumed to reflect the stage of differentiation of those B cells that are expanded 
in the neoplastic process. The high concentration of CD45RO isoforms was found 
among peripheral blood lymphocytes in patients with multiple myeloma and Walden-
strom, s macroglobulinemia, in which the population of B cells are of late B or early 
pre-plasma cells (35). Another view point may suggest that similar to T cell system, 
where CD45RO is expressed not only on mature memory T cells, but also on the major-
ity of immature thymus cells, the expression of CD45RO on CLL cells may reflect rela-
tive immaturity of B-CLL cells. The distribution of CD45RA and CD45RO in our pa-
tients was uniform. Among our patients, 85.5 and 84% expressed CD45RA and 
CD45RO on their leukemic B cells, respectively. Also 70% of the patients coexpressed 
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both isoforms. Two other studies showed that about half of the CLL patients coex-
pressed both CD45 isoforms, while in the remaining patients CLL cells expressed only 
the CD45RA isoform (27, 32). Of our 87 B-CLL cases 13 (14.8%) and 14 (16%) only 
expressed CD45RA and CD45RO, respectively. In the study of Yu et al. (34), most 
CLL cases (91%) expressed CD45RA and only 18% expressed CD45RO (coexpressed 
with CD45RA). In the study of Vilpo et al. (26) all CLL cases expressed CD45RA uni-
formly and their patients had differential expression of CD45RO in which about half of 
the cases expressed CD45RO below the range of 20% of positive cells. The reason for 
the differences in the expression of CD45 isoforms in different groups of CLL patients 
is not clear. Also their role in the pathogenesis of the disease is not clearly defined. In a 
recent study by Matto et al (36), it was suggested that the two isoforms had distinct ef-
fects on BCR or cytokine-induced cellular proliferation of B cells. They showed that 
BCR stimulation significantly increased the proliferation of the follicular lymphoma cell 
line expressing CD45RO (HF28RO cell line), in contrast to a decreased proliferation of 
HF28RA cell line (the same cell line expressing CD45RA). Moreover, proliferation of 
HF28RO cells was significantly increased after the addition of IL-2, 4, 6, 10, 12, 13, 15, 
IFN-Ȗ and TNF-Į, whereas most of these cytokines significantly inhibited the prolifera-
tion of HF28RA cells. 
In conclusion it seems that some membrane molecules may have important roles on the 
proliferation and survival of leukemic B-cells in CLL. Among the most important dif-
ferentially expressed molecules, CD38 may have important role in the progression of 
CLL. The key role of this molecule in the pathogenesis of B-CLL needs further investi-
gation. Our results obtained in an Asian ethnic population confirm and extend previous 
findings obtained from Western populations regarding the association of CD38 expres-
sion and disease progression in B-CLL. 
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